Abstract
This paper represents the first synthesis, spectroscopic characterization, and antitumor evaluation of F-, N-, and S-containing C4α-FA derivatives of podophyllotoxin. In a synthetic strategy, a FA unit of 4-O-podophyllotoxinyl 12-hydroxyoctadec-Z-9-enoate 2, a derivative of podophyllotoxin, was functionalized at the C−12 position by incorporating the F atom and N-containing moieties. The FA olefin (Z, C−9/C−10) of 2 was hydrogenated to produce a derivative possessing a hydroxy function (C−12) on a saturated C18 FA chain. In another synthetic strategy, two S-ethers of podophyllotoxin (C4α) were synthesized from a terminal unsaturated FA analog, 4-O-podophyllotoxinyl undec-10-enoate. Syntheses were achieved through effective synthetic procedures; 1H NMR, 13C NMR, IR, and high-resolution mass data proved excellent tools to characterize these derivatives. In vitro antitumor activity was investigated against a panel of five human neoplastic cell lines, SK-MEL (malignant, melanoma), KB (epidermal carcinoma, oral), BT-549 (ductal carcinoma, breast), SK-OV-3 (ovary carcinoma), and HL-60 (human leukemia). Keeping in view the severe lack of tumor selectivity of podophyllotoxin over normal cells, we assayed new analogs against noncancerous mammalian VERO (African green monkey kidney fibroblast) cell lines to gauge their extent of toxicity. Several of these compounds showed excellent moderation of antitumor activity. In general, we found excellent growth inhibition against the human leukemia cell line (HL-60), particularly for the analogs containing S-ethers and carbamates. None of the compounds were toxic to normal cell lines.
Similar content being viewed by others
Abbreviations
- DAST:
-
diethylaminosulfur trifluoride
- DCC:
-
dicyclohexylcar-bodiimide
- DMAP:
-
dimethyl aminopyridine
- NCI:
-
National Cancer Institute
References
Kauffman, J.M., and Foye, W.O. (1981) Cancer Chemotherapy, in Principles of Medicinal Chemistry (Foye, W.O., ed.), pp. 837–861, Lea and Febiger, Philadelphia.
Haskel, C.M. (1990) Principles of Cancer Chemotherapy, in Cancer Treatment (Haskel, C.M., ed.), pp. 27–52, W.B. Saunders, Philadelphia.
Xi, C.W., and Wang, P.G. (2003) Glucuronides in Anti-cancer Therapy, Curr. Med. Chem.—Anti-cancer Agents 3, 139–150.
Gordaliza, M., Castro, M.A., Miguel del Correl, J.M., and Feliciano, A.S. (2000) Antitumor Properties of Podophyllotoxin and Related Compounds, Curr. Pharm. Design 6, 1811–1839.
Damayanthi, Y., and Lown, J.W. (1998) Podophyllotoxins: Current Status and Recent Developments, Curr. Med. Chem. 5, 205–252.
Jardine, I. (1980) Podophyllotoxin, in Anticancer Agents Based on Natural Product Models (Cassady, J.M., and Douras, J.D., eds.), pp. 319–351, Academic Press, New York.
Keller-Juslen, C., Kuhn, M., Stahelin, H., and von Wartburg, A. (1971) Synthesis and Antimitotic Activity of Glycosidic Lignan Derivatives Related to Podophyllotoxin, J. Med. Chem. 14, 936–940.
Issell, B.F., Muggia, F.M., and Carter, S.K. (eds.) (1984) Etoposide (VP-16): Current Status and New Developments, Academic Press, New York.
van Maanen, J.M.S., Retel, J., De Vries, J., and Pinedo, H.M. (1988) Mechanism of Action of the Antitumor Drug Etoposide, J. Natl. Cancer Inst. 80, 1526–1533.
Lee, K.H. (1999) Novel Anticancer Agents from Higher Plants, Med. Res. Rev. 19, 569–596.
Murdter, T.E., Sperker, B., Kivisto, K.T., McClellan, M., Fritz, P., Friedel, G., Linder, A., Bosslet, K., Toomes, H., Dierkesmann, R., and Kroemer, H.K. (1997) Enhanced Uptake of Doxorubicin into Bronchial Carcinoma: β-Glucuronidase Mediates Release of Doxorubicin from Glucuronide Prodrug (HMR 1826) at the Tumor Site, Cancer Res. 57, 2440–2445.
Menendez, J.A., Ropero, S., Lupu, R., and Colomer, R. (2004) ω-6 Polyunsaturated Fatty Acid γ-Linolenic Acid (18∶3n−6) Enhances Docetaxel (Taxotere) Cytoxicity in Human Breast Carcinoma Cells: Relationship to Lipid Peroxidation and HER-2/neu Expression, Oncol. Rep. 11, 1241–1252.
Moyer, M.P., Hardman, W.E. and Cameron, I. (2003) Accelerated Action Fatty Acid (AAFA) Promotes Health of Normal Tissues and Minimizes the Toxic Side Effects of Chemotherapy, U.S. Patent Application 2002-102907 200220322, Priority: US 2001-278138, 27 pp.
Hardman, W.E., Cameron, I.L., and Moyer, M.P. (2001) Fatty Acids to Minimize Cancer Therapy Side Effects, PCT Intl. Application WO 99-US16666 19990722, 31 pp.
Larsson, S.C., Kumlin, M., Ingelman-Sundberg, M., and Wolk, A. (2004) Dietary Long-Chain n−3 Fatty Acids for the Prevention of Cancer: A Review of Potential Mechanisms, Am. J. Clin. Nutr. 79, 935–945.
Conklin, K.A. (2002) Dietary Polyunsaturated Fatty Acid: Impact on Cancer Chemotherapy and Radiation, Altern. Med. Rev. 7 (1), 4–21.
Bougnoux, P. (1999) n−3 Polyunsaturated Fatty Acids and Cancer, Curr. Opin. Clin. Nutr. Metabol. Care 2, 121–126.
Berge, R. (2002) Fatty Acid Analogues for the Treatment of Cancer, PCT Intl. Application WO 2001-NO301 20010713, 31 pp.
Nagao, Y., Mustafa, J., Sano, S., Ochiai, M., Tazuko, T., and Shigeru, T. (1991) Different Mechanism of Action of Long Chain Fatty Acid Esters of Podophyllotoxin and Esters of Epipodophyllotoxin Against P388 Lymphocytic Leukemia in Mice, Med. Chem. Res. 1, 295–299.
Lie Ken Jie, M.S.F., Mustafa, J., and Pasha, M.K. (1999) Synthesis and Spectral Characteristics of Some Unusual Fatty Esters of Podophyllotoxin, Chem. Phys. Lipids 100, 165–170.
Mustafa, J., Khan, S.I., Ma, G., Walker, L.A., and Khan, I.A. (2004) Synthesis and Anticancer Activities of Fatty Acid Analogs of Podophyllotoxin, Lipids 39, 167–172.
Mustafa, J., Khan, S.I., Ma, G., Walker, L.A., and Khan, I.A. (2004) Synthesis, Spectroscopic and Biological Studies of Novel Estolides Derived from Antitumor Active 4-O-Podophyllotoxinyl 12-Hydroxyl Octadec-Z-9-enoate, Lipids 39, 659–666.
Ma, G., Khan, S.I., Mustafa, J., Walker, L.A., and Khan, I.A. (2005) Anticancer Activity and Possible Mode of Action of 4-O-Podophyllotoxinyl 12-Hydroxyl-octadec-Z-9-enoate, Lipids 40, 303–308.
Field, C.J., and Schley, P.D. (2004) Evidence for Potential Mechanisms for the Effect of Conjugated Linoleic Acid on Tumor Metabolism and Immune Function: Lessons from n−3 Fatty Acids, Am. J. Clin. Nutr. 79 (6 Suppl.), 1190S-1198S.
Akihisa, T., Tokuda, H., Ogata, M., Ukiya, M., Iizuka, M., Suzuki, T., Metori, K., Shimizu, N., and Nishino, H. (2004) Cancer Chemopreventive Effects of Polyunsaturated Fatty Acids, Cancer Lett. 205, 9–13.
Fearon, K.C.H. (2002) The Anticancer and Anticachectic Effects of n−3 Fatty Acids, Clin. Nutr. 21 (Suppl. 2), S73-S77.
Tronstad, K.J., Berge, K., Berge, R.K., and Bruserud, O. (2003) Modified Fatty Acids and Their Possible Therapeutic Targets in Malignant Diseases, Expert Opin. Ther. Targets 7, 663–677.
Stelzer, U., and Effenberger, F. (1993) Preparation of (S)-Fluoronitriles, Tetrahedron Asymm 4, 161–164.
Focella, A., Bizzarro, F., and Exon, C. (1991) Simple Stereospecific Syntheses of (R)-Fluorohexanoic Acid Ethyl Ester, Synth. Commun. 21, 2165–2170.
Leroy, J., Hebert, E., and Wakselman, C. (1979) Maximum Optical Rotation of 2-Fluorooctane? Survey of Fluorinating Reagents, J. Org. Chem. 44, 3406–3408.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Mustafa, J., Khan, S.I., Ma, G. et al. Synthesis and in vitro cytotoxic activity of N-, F-, and S-ether derivatives of podophyllotoxin fatty acid adducts. Lipids 40, 375–382 (2005). https://doi.org/10.1007/s11745-006-1397-x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11745-006-1397-x